Express Grants of ‘Apixaban’ Patent is 121st Process Patent

August30, 2017 (C) Ravinder Singh

It is shocking none of our News Media bothered to ascertain facts about ‘Patent Granted by Indian Patent Office in 113 days’ – after waiting for a fortnight I decided to DISCLOSE FACTS. No Exclusivity for this invention – 3 Original Patents and 121 Process Patents.


Ø Cadila India filed US Patent in 2014, filed in India recently & granted speedily. Its priority date is Nov25, 2014 – so at least 30 months or more.

Ø But it is Not Original Invention – it dates back to Sep21, 2001.

Ø Cadila merely filed a process


Apixapan at least 17 Yrs Old Invention – 121 Process Patents

Apixaban is the generic ingredient in one branded drug marketed by Bristol Myers Squibb and is included in one NDA. There are three patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.
Apixaban has 
one hundred and twenty-one patent family members in forty countries.
There are twenty-four drug master file entries for apixaban. Two suppliers are listed for this compound.


I have attached Patent Ownership of few Important Apixaban Drug.


India has not yet learnt to ‘Create Original Inventions’ and Protecting & Commercialize them worldwide.


Ravinder Singh, Inventor & Consultant, INNOVATIVE TECHNOLOGIES AND PROJECTS

Y-77, Hauz Khas, ND -110016, India. Ph: 091- 9871056471, 9718280435, 9650421857

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s